fondaparinux decreases Deep Vein Thrombosis and Pulmonary embolism in SVT patients

A new meta-analysis has shown that fondaparinux may be effective drug treatment for superficial vein thrombosis (SVT) in reducing the rate of Deep Vein Thrombosis (DVT) and Pulmonary embolism (PE). The study was publshed in the journal Thieme.

Superficial venous thrombosis is inflammation of the superficial veins associated with venous thrombosis. Superficial venous thrombosis (SVT) has received increased attention as more clinicians are recognizing the potential morbidity of untreated disease. The optimal first-line treatment for the treatment of superficial venous thrombosis. The incidence of deep vein thrombosis (DVT) has been reported to be 6%–40%, with symptomatic pulmonary embolism occurring in 2%–13% of patients, and asymptomatic pulmonary embolism occurring in up to one-third of patients with SVT

The systemic review and meta-analysis were performed using an electronic database which analyzed 17 articles and 6,862 patients. The primary outcome was the occurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE) during the study follow-up period. the patients were treated with the nonsteroidal anti-inflammatory drug (NSAIDs), anticoagulant therapies, surgical therapies, and observation/placebo, after search across electronic databases. Incidence of DVT or PE during the follow-up period were evaluated.

The researchers found that Fondaparinux had the lowest event rate with 1.4 events per 100 patient-years of follow-up (95% confidence interval. Pooled event rates for DVT or PE ranged from 9.3 to 16.6 events per 100 patient-years across other treatment categories, and the pooled event rate for no treatment/placebo was 10.5 events per 100 patient-years. Major bleeding was low and similar across all treatment categories. Heterogeneity was moderate to high for most pooled estimates.

Based on the pooled analysis the authors concluded that the absolute event rates were lower across all treatment options for the most clinically significant outcomes. The authors suggested that treatment should be individualized, including patient preference and weigh the burden of follow-up visits and imaging and cost and convenience between oral or parenteral anticoagulants.

To know more about the study click on the link

DOI: 10.1055/s-0039-1677793